Pfiz­er's in­vest­ment fund is mak­ing waves in VC — in­clud­ing a $25M bet on IBD play­er Vedan­ta Bio­sciences

Pfiz­er has a gut feel­ing about Vedan­ta Bio­sciences.

On Tues­day, the Cam­bridge, Mass­a­chu­setts-based mi­cro­bio­me up­start be­came the fourth biotech to re­ceive an in­vest­ment from the Pfiz­er Break­through Growth Ini­tia­tive (PG­BI), bag­ging $25 mil­lion to send its in­flam­ma­to­ry bow­el dis­ease can­di­date to Phase II.

Since its launch in June, the PG­BI has in­vest­ed $120 mil­lion in small- to medi­um-sized biotechs span­ning sev­er­al key fo­cus ar­eas: in­ter­nal med­i­cine, in­flam­ma­tion and im­munol­o­gy, on­col­o­gy, rare dis­ease, vac­cines and hos­pi­tal. So far, Ho­mol­o­gy Med­i­cines has the largest stake, with $60 mil­lion to ad­vance its phenylke­tonuria (PKU) pro­gram.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER